SINGAPORE, April 10, 2025 — Cuprina Holdings (Cayman) Limited (“CUPR” or “the Company“), a company focused on biomedical and biotechnology, announced the pricing of its initial public offering of 3,000,000 Class A Ordinary Shares at $4.00 per share (“the Offering Price“).
The underwriter has been granted the option to purchase up to 450,000 additional Class A Ordinary Shares, representing 15% of the shares sold in the Offering (“the Over-allotment“), within a 45-day period.
Assuming the Over-allotment option is fully exercised, the Company anticipates receiving gross proceeds of $13.80 million before deducting underwriting discounts, commissions, and other offering-related expenses.
The shares are anticipated to commence trading on the NASDAQ Stock Market LLC under the ticker symbol “CUPR” on April 10, 2025, with the Offering expected to close on April 11, 2025, contingent upon standard closing conditions.
R. F. Lafferty & Co., Inc. (“R. F. Lafferty”) served as the sole book-running manager for the Offering. Loeb & Loeb LLP, Lee & Lee, Harney Westwood & Riegels Singapore LLP are serving as U.S., Singapore and Cayman Islands legal counsels to the Company, respectively, and Winston & Strawn LLP is serving as U.S. legal counsel to R. F. Lafferty for the Offering.
The Offering is being made through the Company’s Registration Statement on Form F-1 (File No: 333-283643), which was previously filed with the U.S. Securities and Exchange Commission (“SEC”) and declared effective on March 31, 2025. The offering is being made only by means of a prospectus. Investors should review the prospectus and other documents filed or to be filed with the SEC for detailed information about the Company and the Offering before investing. Copies of the final prospectus, when available, can be obtained from R. F. Lafferty & Co., Inc. at 40 Wall Street, 27th Floor, New York, NY 10005, by phone at (212) 293-9090, or via email at offerings@rflafferty.com. The final prospectus will also be available on the SEC’s website at .
This announcement is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities. The securities will not be offered or sold in the United States without registration or an applicable exemption from registration, nor will any offer, solicitation, or sale occur in any jurisdiction where such action would be unlawful prior to registration or qualification under local securities laws.
FORWARD-LOOKING STATEMENTS
This press release contains statements regarding future expectations, plans, and prospects, and other statements that are not historical facts, which may be considered “forward-looking statements” under the Private Securities Litigation Reform Act of 1995. These statements include those related to the anticipated commencement of trading and closing dates. Terms like “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” and similar expressions, are used to identify forward-looking statements. However, not all forward-looking statements contain these words. Actual results may differ significantly from those indicated in the forward-looking statements due to various factors, including market conditions, the successful completion of the public offering, and other risks detailed in the “Risk Factors” section of the preliminary prospectus filed with the SEC. Investors are cautioned against placing undue reliance on these statements, which speak only as of the date of this press release. Cuprina Holdings (Cayman) Limited disclaims any obligation to update these statements, whether due to new information, future events, or otherwise, except as required by law.
About Cuprina Holdings (Cayman) Limited
Based in Singapore, we are a biomedical and biotechnology company focused on developing and commercializing innovative products for chronic wound management, as well as operating in the health and beauty sectors. We leverage our biomedical research expertise to identify and utilize natural materials to develop wound care products that meet international standards. Additional information is available at https:// www.cuprina.com.
Cuprina Holdings (Cayman) Limited Investor Contact
Investor Relations
c/o Blk 1090 Lower Delta Road #06-08
Singapore 169201
+65 8512 7275
Email:
Investor Relations Inquiries:
Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor
New York, New York 10036
Office: (646) 893-5835
Email:
“`